Loading...
Guest User
Welcome! Please login.
* - Tentative Dates
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
| Period Ended | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 195.91 | 109.60 |
| Revenue | 91.99 | 63.41 |
| Profit After Tax | -18.31 | -31.05 |
| Net Worth | ||
| Reserves and Surplus | ||
| Total Borrowing |
Brooks Laboratories Limited was established in January 2002. The company is engaged in the manufacture and marketing of pharmaceuticals both domestically and internationally. Brooks Laboratories is a pharmaceutical contract research and manufacturing company that offers a wide range of intensive care products for parents, such as beta-lactam, general dry powder injectables, ampoules and liquid vials, dry syrups and tablets, etc. The product range includes:
The company's products face strong competition from products marketed or under development by competitors in all therapeutic areas. They compete with local companies, multinational corporations and companies from the rest of the world. The company faces significant competition from other large and small pharmaceutical companies. They compete based on a number of factors, including execution, depth of product and service offerings, innovation, reputation, and price.
In a short period of time, Brooks Laboratories has developed its own marketing and training department. The training department trains all sales staff prior to their introduction, while the marketing department oversees the proper formulation and execution of marketing strategies. The Group has its own strong supply chain with more than 300 distributors. This ensures smooth transportation of goods and quick availability.
